You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

Taro Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Taro
International Patents:24
US Patents:5
Tradenames:137
Ingredients:120
NDAs:260
Patent Litigation for Taro: See patent lawsuits for Taro
PTAB Cases with Taro as petitioner: See PTAB cases with Taro as petitioner

Drugs and US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro FLUOCINOLONE ACETONIDE fluocinolone acetonide CREAM;TOPICAL 087104-001 Apr 27, 1982 AT RX No No ⤷  Try for Free ⤷  Try for Free
Taro WARFARIN SODIUM warfarin sodium TABLET;ORAL 040301-002 Jul 15, 1999 AB RX No No ⤷  Try for Free ⤷  Try for Free
Taro CLOBETASOL PROPIONATE clobetasol propionate GEL;TOPICAL 075279-001 May 28, 1999 AB RX No No ⤷  Try for Free ⤷  Try for Free
Taro BETAMETHASONE DIPROPIONATE betamethasone dipropionate LOTION;TOPICAL 074272-001 Sep 30, 1994 DISCN No No ⤷  Try for Free ⤷  Try for Free
Taro CLOBETASOL PROPIONATE clobetasol propionate LOTION;TOPICAL 200302-001 Jul 2, 2012 AB RX No No ⤷  Try for Free ⤷  Try for Free
Taro DESONIDE desonide OINTMENT;TOPICAL 074254-001 Aug 3, 1994 AB RX No No ⤷  Try for Free ⤷  Try for Free
Taro MINOXIDIL (FOR WOMEN) minoxidil SOLUTION;TOPICAL 218175-001 Nov 26, 2024 OTC No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 6,656,482 ⤷  Try for Free
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 5,881,926 ⤷  Try for Free
Taro TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 5,990,100 ⤷  Try for Free
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 6,656,482 ⤷  Try for Free
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 6,399,079 ⤷  Try for Free
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 6,399,079 ⤷  Try for Free
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 6,071,523 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TARO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18

Supplementary Protection Certificates for Taro Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 2001C/045 Belgium ⤷  Try for Free PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0984957 122012000017 Germany ⤷  Try for Free PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
1304992 2013C/060 Belgium ⤷  Try for Free PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
1411900 2011C/016 Belgium ⤷  Try for Free PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1620113 C 2015 036 Romania ⤷  Try for Free PRODUCT NAME: IVERMECTINA; NATIONAL AUTHORISATION NUMBER: RO7674/2015/01, RO7674/2015/02, RO7674/2015/03, RO7674/2015/04, RO7674/2015/05; DATE OF NATIONAL AUTHORISATION: 20150526; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): MALTA MA117/01101; DATE OF FIRST AUTHORISATION IN EEA: 20150402
0617614 C300043 Netherlands ⤷  Try for Free PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
1458369 122008000041 Germany ⤷  Try for Free PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Taro – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Taro Pharmaceutical Industries Ltd., a global player in the industry, has carved out a significant niche for itself. Let's dive into an in-depth analysis of Taro's market position, strengths, and strategic insights that shape its competitive edge.

Taro Pharmaceutical Industries: An Overview

Taro Pharmaceutical Industries Ltd. is a research-based pharmaceutical manufacturer that has been steadily growing since 2008[1]. Founded in 1950 and headquartered in Haifa, Israel, Taro has established itself as a key player in the development, manufacture, and marketing of prescription and over-the-counter pharmaceutical products[3].

Core Business Model

Taro's business model is multifaceted, focusing on producing high-quality medications across various therapeutic categories[3]. The company's approach includes:

  1. Significant investment in Research and Development (R&D)
  2. Focus on generic pharmaceuticals
  3. State-of-the-art manufacturing facilities
  4. Global operations with a strong presence in North America, Europe, and Asia
  5. Diverse product portfolio spanning multiple therapeutic areas

Financial Performance

Taro's financial trajectory has been impressive. Its revenues increased from $327 million in 2008 to over $850 million in 2014[1]. This growth trend has been accompanied by a substantial increase in earnings per share, rising from $0.76 to an estimated $13.00 during the same period[1].

Market Position and Competitive Landscape

Taro operates in a highly competitive pharmaceutical market, facing competition from both generic and branded pharmaceutical companies[3].

Market Share

As of Q1 2023, Taro held a market share of 0.26% within the Major Pharmaceutical Preparations Industry[9]. While this might seem small, it's important to note that the pharmaceutical industry is highly fragmented, with even major players like Johnson & Johnson holding around 39.42% market share[9].

Key Competitors

Some of Taro's main competitors include:

  1. Teva Pharmaceutical Industries Limited (6.81% market share)
  2. Viatris Inc (7.52% market share)
  3. Perrigo Company Plc (1.98% market share)
  4. Amneal Pharmaceuticals Inc (0.94% market share)[9]

Taro's Strengths in the Competitive Landscape

1. Robust R&D Capabilities

Taro's commitment to research and development is a cornerstone of its growth strategy[7]. The company develops high-quality, proprietary, and off-patent pharmaceuticals for markets worldwide[7]. This focus on innovation allows Taro to continuously expand its product portfolio and stay competitive in the rapidly evolving pharmaceutical industry.

2. Vertical Integration

One of Taro's significant strengths is its vertical integration. The company not only produces finished dosage forms but also synthesizes many of the active ingredients used in its key products[7]. This integration provides Taro with several competitive advantages:

  • Quality control over the entire manufacturing process
  • Reliability of supply
  • Cost advantages in active pharmaceutical ingredients

3. Diverse Product Portfolio

Taro offers a wide range of products across various therapeutic categories, including:

  • Dermatology
  • Cardiology
  • Neurology
  • Analgesics
  • Gastroenterology[3]

This diversity helps Taro mitigate risks associated with market fluctuations in specific therapeutic areas.

4. Global Presence

Taro has a strong global presence, with operations in over 20 countries[1]. Its key markets include:

  • United States
  • Canada
  • Israel

This global footprint allows Taro to tap into various markets and diversify its revenue streams.

"Taro Pharmaceutical Industries is reported to be on steady growth since 2008. Its revenues have increased from $327 million to over $850 on 2014, and at the same time, its earnings per share have been increasing from $0.76 to an estimated $13.00 during this period."[1]

Strategic Insights: Taro's Approach to Market Dominance

1. Focus on Generic Pharmaceuticals

Taro's strategic focus on generic pharmaceuticals allows it to provide affordable alternatives to brand-name drugs[3]. This approach positions Taro well in a market increasingly focused on cost-effective healthcare solutions.

2. Investment in Manufacturing Excellence

Taro maintains state-of-the-art manufacturing facilities, primarily located in Israel and the United States[3]. These facilities adhere to stringent quality standards, ensuring compliance with regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)[3].

3. Multi-Channel Distribution Strategy

Taro utilizes a multi-channel distribution strategy that includes:

  • Wholesalers
  • Retail drug chains
  • Healthcare institutions
  • Direct-to-consumer channels[3]

This diverse distribution approach helps Taro reach a wide range of customers and maintain a strong market presence.

4. Customer Engagement Initiatives

Taro emphasizes customer engagement by providing comprehensive support to healthcare providers and patients[3]. These initiatives include:

  • Educational resources
  • Patient assistance programs
  • Direct communication channels

SWOT Analysis: Understanding Taro's Position

Strengths

  • Strong market presence
  • Extensive distribution networks
  • Diverse product portfolio
  • Vertical integration
  • Robust R&D capabilities

Weaknesses

  • Relatively small market share compared to industry giants
  • Dependence on generic drug market
  • Potential vulnerability to regulatory changes

Opportunities

  • Expansion into emerging markets
  • Development of new drug formulations
  • Potential for strategic partnerships or acquisitions

Threats

  • Intense competition in the generic drug market
  • Regulatory hurdles
  • Potential for supply chain disruptions
  • Patent expirations of branded drugs

Future Outlook: Taro's Path Forward

As Taro navigates the future, several factors will likely shape its competitive position:

  1. Continued Innovation

    Taro's ongoing investment in R&D will be crucial for developing new products and maintaining its competitive edge.

  2. Market Expansion

    Exploring opportunities in emerging markets could provide new avenues for growth.

  3. Digital Transformation

    Embracing digital technologies in manufacturing, distribution, and customer engagement could enhance Taro's operational efficiency and market reach.

  4. Sustainability Initiatives

    As sustainability becomes increasingly important in the pharmaceutical industry, Taro's approach to environmental and social responsibility could impact its market position.

  5. Regulatory Navigation

    Taro's ability to navigate complex and evolving regulatory landscapes will be crucial for its continued success.

Key Takeaways

  • Taro Pharmaceutical Industries has shown steady growth since 2008, with significant increases in revenue and earnings per share.
  • The company's strengths lie in its robust R&D capabilities, vertical integration, diverse product portfolio, and global presence.
  • Taro's focus on generic pharmaceuticals and investment in manufacturing excellence are key strategic approaches.
  • While Taro faces intense competition and regulatory challenges, opportunities for growth exist in emerging markets and new drug formulations.
  • The company's future success will likely depend on continued innovation, market expansion, digital transformation, and effective regulatory navigation.

FAQs

  1. What are Taro Pharmaceutical Industries' main product categories?

    Taro's main product categories include dermatology, cardiology, neurology, analgesics, and gastroenterology.

  2. How does Taro's vertical integration provide a competitive advantage?

    Taro's vertical integration allows for quality control over the entire manufacturing process, reliability of supply, and cost advantages in active pharmaceutical ingredients.

  3. What is Taro's market share in the Major Pharmaceutical Preparations Industry?

    As of Q1 2023, Taro held a market share of 0.26% within the Major Pharmaceutical Preparations Industry.

  4. How does Taro's R&D strategy contribute to its competitive position?

    Taro's significant investment in R&D allows it to continuously develop new and innovative pharmaceutical products, helping it stay competitive in the rapidly evolving industry.

  5. What are some of the key challenges Taro faces in the pharmaceutical market?

    Key challenges include intense competition in the generic drug market, regulatory hurdles, potential supply chain disruptions, and patent expirations of branded drugs.

Sources cited: [1] https://www.tarointl.com [3] https://pitchgrade.com/companies/taro-pharmaceutical-industries [7] https://www.taro.com/research [9] https://csimarket.com/stocks/competitionSEG2.php?code=TARO

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.